Journal profile · Advances in Cell and Gene Therapy
Advances in Cell and Gene Therapy
ISSN 2573-8461 · John Wiley & Sons, Inc. · USA
Advances in Cell and Gene Therapy: fully open access; APC about USD 840; review about 100 days (submission to acceptance, publisher); community-reported acceptance: 23%; 4 articles in 2025.
Scope
Aims, scope and focus
Advances in Cell and Gene Therapy is published by John Wiley & Sons, Inc.. By OpenAlex counts of its recent articles, its largest topics are CAR-T cell therapy research, Hematopoietic Stem Cell Transplantation and Immunotherapy and Immune Responses, together about 35.7% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Advances in Cell and Gene Therapy is an international journal publishing original, high-quality, peer-reviewed articles which cover basic and clinical research relating to advances in cell, gene, and immune therapies and their use in the treatment of a wide range of diseases, including cancer, genetic and immune diseases, and others. The topics the journal covers include cell, gene and immune therapies in children and adults with a wide range of disorders, including cancers, genetic and immune diseases, and others. All articles include a section or feature detailing the current and future clinical implications of the research. Among the extensive and provocative reviews, Advances in Cell and Gene Therapy provides a forum for presenting original research articles and sharing ideas for innovation, as well as disseminating knowledge of primary clinical relevance to advance patient care.
From the journal's Aims & Scope
Research area (LetPub): Advances in Cell and Gene Therapy
Editor-in-chief Carol MiaoPublisher website
Editorial board by country: none in mainland China; most named United States 3, Hong Kong, China 1, India 1 (5 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- CAR-T cell therapy researchMedicine14.5%
- Hematopoietic Stem Cell TransplantationMedicine14.1%
- Immunotherapy and Immune ResponsesImmunology and Microbiology7.1%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology7.1%
- Acute Myeloid Leukemia ResearchMedicine6.2%
- Lymphoma Diagnosis and TreatmentMedicine5.4%
- T-cell and B-cell ImmunologyImmunology and Microbiology4.6%
- Multiple Myeloma Research and TreatmentsMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
Indexed in: no record yet.
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- h-index
- 12OpenAlex ·
- i10-index
- 18OpenAlex ·
- 2-year mean citedness
- 1OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year (publisher) 2025
- 3Publisher website ·
- Downloads per year (publisher) 2025
- 22,184Publisher website ·
Articles by year OpenAlex count · 135 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 0 | 0 | 63 |
| 2025 | 4 | 3 | 105 |
| 2024 | 2 | 2 | 112 |
| 2023 | 6 | 6 | 102 |
| 2022 | 6 | 4 | 143 |
| 2021 | 12 | 6 | 109 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
Too few articlesOnly 3 articles from the last 24 months carry both submission and acceptance dates, too few for a median
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Figures by source
- Average acceptance (community reports)
- 23%LetPub ·
- Acceptance rate (publisher)
- 23%Publisher website ·
- Acceptance rate (publisher) 2025
- 23%Publisher website ·
- Submission to first decision
- 43 daysPublisher website ·
- Submission to first decision 2025
- 43 daysPublisher website ·
- Submission to acceptance 2025
- 100 daysPublisher website ·
- Acceptance to publication 2025
- 22 daysPublisher website ·
- Submission to publication
- 43 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 840 / EUR 720 / GBP 620 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted4
- editorialAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
- letter to the editorAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
- original researchAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
- review articleAdvances in Cell and Gene Therapy publishes the following types of submissions: Original Research Review Article Editorial Letter to the EditorLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints, Self-archiving, Trial registration / reporting guidelines
- AI use Disclosing the use of artificial intelligence (AI)
If you or your co-authors have used Artificial Intelligence Generated Content (AIGC) tools such as ChatGPT and others based on large language models (LLMs) to develop any portion of a manuscript, their use must be described transparently and in detail in the Methods section. Find more details on Wiley’s AI guidelines for researchers and Wiley’s AI policy in full in the Best Practices Guidelines on…
Source ↗Publisher website ·- Authorship Authorship
Author name change policy: Wiley updates and republishes. Model summary
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. You can review the Authorship section of Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics for Wiley’s definition of authorship.
Source ↗Publisher website ·- Conflicts of interest Conflicts of Interest (COIs)
A common reason for third-party complaints of published articles is an allegation that author(s) have not fully disclosed perceived conflicts of interest (COIs). Such complaints may lead to ethics investigations by the journal and publisher. Therefore, when submitting your manuscript, you should disclose any potential conflicts of interests (also referred to as “competing interests”) that might ap…
Source ↗Publisher website ·- Data availability Data Sharing
Data availability statement required. Model summary
This journal encourages data sharing. You can learn more about data sharing in Wiley’s Data Sharing Policies resource.
Source ↗Publisher website ·- Publication ethics COPE
This journal adheres to the ethical standards set by the Committee on Publication Ethics (COPE) to uphold integrity in scholarly research and publishing. While COPE previously organized its guidance around "core practices," these have since been replaced with a topic-based structure to better reflect the evolving needs of the research community. You can learn more about this transition and explore…
Source ↗Publisher website ·- License & copyright Copyright and licensing
This is an open access journal. Authors of accepted papers pay an Article Publication Charge (APC) and their papers are published under a Creative Commons (CC) license. For more information on this journal’s APCs and licensing policy, please visit this journal’s Open Access page. Note: Some funders require authors to use a particular type of CC license. Please check directly with your funder to de…
Source ↗Publisher website ·- Open access Open access
Open access journal Model summary
This is an open access journal. Submissions will be subject to an Article Publication Charge (APC) if accepted and published in the journal. Please read more about APCs and whether you may be eligible for waivers or discounts through your institution, your funder, or a country waiver at Wiley Author Services.
Source ↗Publisher website ·- Peer review Peer Review Model
Peer review model: single-anonymized for applicable article types. Model summary
We follow a single-anonymized peer review model, for applicable article types. Except where otherwise stated, manuscripts are peer reviewed by at least one anonymous reviewer and an Associate or Assistant Editor. Papers authored by Editors or Editorial Board members of the journal will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer…
Source ↗Publisher website ·- Preprints Preprint Policy
Preprint policy: accepts preprint-published articles. Model summary
The journal accepts articles previously published on preprint servers and does not consider this to compromise the novelty of the results. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered. The preprint should be cited. You will be asked to update any pre-publication versions with a link to the final published ar…
Source ↗Publisher website ·- Self-archiving Self-Archiving definitions and policies
Self-archiving allowed under specific conditions. Model summary
This journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. You can learn more by reading Wiley’s self-archiving policy.
Source ↗Publisher website ·- Trial registration / reporting guidelines Reporting guidelines
Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximize transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of: Wiley Biological and Biomedical Scienc…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley & Sons, Inc.
- Country or region
- USA
- Language
- English
- ISSN
- 2573-8461
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Advances in Cell and Gene Therapy
How long does peer review take at Advances in Cell and Gene Therapy?
The publisher reports about 100 days (submission to acceptance); the community-reported acceptance is “23%”; the journal's website gives an acceptance rate of 23% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Advances in Cell and Gene Therapy based?
Of the 5 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (3), Hong Kong, China (1) and India (1). Counted from the institutions listed on the board page; for reference only.
Is Advances in Cell and Gene Therapy open access, and what is the APC?
Advances in Cell and Gene Therapy is a fully open-access journal. APC about USD 840.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .